|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | QIAGEN (Nasdaq:QGEN), a provider of sample and assay technologies for research in life sciences and molecular diagnostics. |
|---|---|
| Transferring Party | eGene, Inc. (Nasdaq:EGEI), an early-stage company that is commercializing a patented sample separation and analysis technology based on capillary electrophoresis. |
| Sector | Diagnostics |
| Date | July 10, 2007 |
| Analysis The combination of patented multiplex fluorescence detection designs with solid-state light sources and micro-optical collectors said to create an advantage over conventional gel-based sample separation technologies. The eGene solutions leverage QIAGEN sample and assay technologies. Deal value -- $34m, on expected sales of approx. $8m (4.2x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |